Defining and characterizing drug/compound function

Biochemical Pharmacology

Volumn 87, Issue 1, 2014, Pages 40-63

  Kenakin, Terry ^a   Williams, Michael ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Compound function; Receptor theory; Receptors

Indexed keywords

CELL SURFACE RECEPTOR; DRUG; LIGAND;

ALLOSTERISM; ARTICLE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; IN VIVO STUDY; INVERSE AGONISM; MOLECULAR BIOLOGY; NONHUMAN; PARTIAL AGONISM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

COMPOUND FUNCTION; RECEPTOR THEORY; RECEPTORS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; LIGANDS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84892367339     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.07.033     Document Type: Article

References (114)

1. BPS/IUPHAR guide to pharmacology, April 2013 http://www. guidetopharmacology.org/targets.jsp
2. S.P. Alexander, A. Mathie, and J.A. Peters Guide to receptors and channels (GRAC), 5th ed. Br J Pharmacol 164 Suppl 1 2011 S1 S324
3. Kenakin, and TP New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review Br J Pharmacol 168 2013 554 575
4. M. Nys, D. Kesters, and C. Ulens Structural insights into Cys-loop receptor function and ligand recognition Biochem Pharmacol 2013 (in press)
5. U.M. Zanger, and M. Schwab Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation Pharmacol Ther 138 2013 103 141
6. J.A. Endicott, M.E.M. Noble, and L.N. Johnson The structural basis for control of eukaryotic protein kinases Annu Rev Biochem 81 2012 587 613
7. M.K. De Gorter, C.Q. Xia, J.J. Yang, and Kim RB Drug transporters in drug efficacy and toxicity Annu Rev Pharmacol Toxicol 52 2012 249 273
8. K.M. Giacomini, S.M. Huang, D.J. Tweedie, L.Z. Benet, K.L. Brouwer, and X. Chu et al. Membrane transporters in drug development Nat Rev Drug Discov 9 2010 215 236
9. T. Kenakin, and A. Christopoulos Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nat Rev Drug Discov 12 2013 205 216
10. A.-H. Maehle, C.-Y. Prüll, and R.F. Halliwell The emergence of the drug receptor theory Nat Rev Drug Discov 1 2002 637 641 (Pubitemid 37361525)
11. A.J. Clark General pharmacology Heffner's Handbuch Der Experimentellen Pharmacologie Ergänzungsband, Band 4 1937 Springer-Verlag Berlin
12. J.H. Gaddum The action of adrenaline and ergotamine on the uterus of the rabbit J Physiol 61 1926 141 150
13. E.J. Ariens Affinity and intrinsic activity in the theory of competitive inhibition Arch Int Pharmacodyn Ther 99 1954 32 49
14. Stephenson RP A modification of receptor theory Br J Pharmacol 11 1956 379 393
15. J.W. Black, and P. Leff Operational models of pharmacological agonist Proc R Soc Lond [Biol] 220 1983 141 162
16. H.P. Rang The receptor concept: pharmacology's big idea Br J Pharmacol 147 2006 S9 S16
17. T. Kenakin, D.B. Bylund, M.L. Toews, K. Mullane, R.J. Winquist, and M. Williams Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century Biochem Pharmacol 87 2014 64 77
18. D.B. Bylund, and M.L. Toews Quantitative versus qualitative data: the numerical dimensions of drug action Biochem Pharmacol 87 2014 25 39
19. M. Williams Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept? Biochem Pharmacol 70 2005 1707 1716 (Pubitemid 41612001)
20. J.C. Buckingham An agenda for UK clinical pharmacology: integrating pharmacology and clinical pharmacology in universities Br J Clin Pharmacol 73 2012 861 865
21. D. Colquhoun Imprecision in presentation of binding studies Trends Pharmacol Sci 6 1985 197
22. T. Kenakin Inverse, protean, and ligand-selective agonism: matters of receptor conformation FASEB J 15 2001 598 611 (Pubitemid 32245978)
23. J.W. Black, P. Leff, and N.P. Shankley An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation Br J Pharmacol 84 1985 561 571 (Pubitemid 15169246)
24. T.P. Kenakin The relative contribution of affinity and efficacy to agonist activity: organ selectivity of noradrenaline and oxymetazoline with reference to the classification of drug receptor Br J Pharmacol 81 1984 131 141 (Pubitemid 14148325)
25. T.P. Kenakin Agonist-receptor efficacy II: agonist-trafficking of receptor signals Trends Pharmacol Sci 16 1995 232 238
26. T.P. Kenakin Perspectives in pharmacology: functional selectivity and biased receptor signaling J Pharmacol Exp Ther 336 2011 296 302
27. J.D. Violin, S.M. DeWire, D. Yamashita, D.H. Rominger, L. Nguyen, and K. Schiller et al. Selectively engaging β-arrestins at the angiotensin II Type 1 receptor reduces blood pressure and increases cardiac performance J Pharmacol Exp Ther 335 2010 572 579
28. D. Gesty-Palmer, M. Chen, E. Reiter, S. Ahn, C.D. Nelson, and S. Wang et al. Distinct β-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation J Biol Chem 281 2006 10856 10864 (Pubitemid 43855508)
29. D. Gesty-Palmer, P. Flannery, L. Yuan, L. Corsino, R. Spurney, and R.J. Lefkowitz et al. β-Arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation Sci Transl Med 1 2009 1ra1
30. S.L. Ferrari, D.D. Pierroz, V. Glatt, D.S. Goddard, E.N. Bianchi, and F.T. Lin et al. Bone response to intermittent parathyroid hormone is altered in mice bull for β-arrestin 2 Endocrinology 146 2005 1854 1862 (Pubitemid 40396895)
31. J.R. Chen, S.M. DeWire, J.J. Kovacs, C.M. Lam, R.J. Lefkowitz, and M.J. Muehlbauer et al. β-Arrestin-1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice J Clin Invest 119 2009 1312 1321
32. K.M. Raehal, J.K.L. Walker, and L.M. Bohn Morphine side effects in β-arrestin 2 knockout mice J Pharmacol Exp Ther 314 2005 1195 1201 (Pubitemid 41205984)
33. L. Bohn, R.J. Lefkowtiz, R.R. Gainetdinov, K. Peppel, M.G. Caron, and F.-T. Lin Enhanced morphine analgesia in mice lacking beta-arrestin 2 Science 286 1999 2495 2498
34. N. Sonoda, T. Imamura, T. Yoshizaki, J.L. Babendure, J.-C. Lu, and Olefsky JM β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells Proc Natl Acad Sci USA 105 2008 6614 6619 (Pubitemid 351754555)
35. T.P. Kenakin Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 6 2007 1393 1401
36. Y.C. Lu Baculoviral vectors for gene delivery: a review Curr Gene Ther 8 2008 54 65
37. Kenakin TP Pharmacological onomastics: what's in a name? Br J Pharmacol 153 2008 432 438
38. S. Mukhopadhyay, and A.C. Howlett Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions Mol Pharmacol 67 2005 2016 2024 (Pubitemid 41007783)
39. M. Metra, L. Dei Cas, A. di Lenarda, and P. Poole-Wilson Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev 9 2004 123 130 (Pubitemid 39485473)
40. D. Borsook, L.R. Beccera, E. Bullmore, and R.J. Hargreaves Imaging in CNS drug discovery and development: implications for disease and therapy 2009 Springer New York
41. D. Horvath, and C. Jeandenans Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces - a novel understanding of the molecular similarity principle in the context of multiple receptor binding profiles J Chem Inf Comput Sci 43 2003 680 690
42. E. Lounkine, M.J. Keiser, S. Whitebread, D. Mikhailov, J. Hamon, and J.L. Jenkins et al. Large-scale prediction and testing of drug activity on side-effect targets Nature 486 2012 361 367
43. R.D. Porsolt, S. Picard, and P. Lacroix International safety pharmacology guidelines (ICH S7A and S7B): where do we go from here? Drug Dev Res 64 2005 83 89 (Pubitemid 40756861)
44. G.A. Gintant An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation Pharmacol Ther 129 2011 109 119
45. L. Urban, S. Whitebread, J. Hamon, D. Mikhailov, and K. Azzaoui Screening for safety relevant off-target activities J.-U. Peters, Polypharmacology in drug discovery 2012 Wiley Hoboken 15 46
46. T. Kenakin Predicting therapeutic value in the lead optimization phase of drug discovery Nat Rev Drug Discov 2 2003 429 438 (Pubitemid 37361724)
47. B.L. Roth, D.J. Sheffler, and W.K.W.K. Kroeze Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat Rev Drug Discov 3 2004 353 359 (Pubitemid 38499762)
48. K. Strebhardt, and A. Ullrich Paul Ehrlich's magic bullet concept: 100 years of progress Nat Rev Cancer 8 2008 473 480 (Pubitemid 351752547)
49. D. Brown Unfinished business: target-based drug discovery Drug Discov Today 12 2007 1007 1012 (Pubitemid 350180564)
50. S.J. Enna, and M. Williams Challenges in the search for drugs to treat central nervous system disorders J Pharmacol Exp Ther 329 2009 404 411
51. J.-U. Peters Polypharmacology in drug discovery 2012 Wiley Hoboken
52. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, and B.T. Campbell et al. A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 2008 127 132
53. MørkA, L.P. Montezinho, S. Miller, C. Trippodi-Murphy, N. Plath, and Y. Li et al. Vortioxetine (Lu AA21004), a novelmultimodal antidepressant, enhances memory in rats Pharmacol Biochem Behav 105 2013 41 50
54. K. Maeda, H. Nakata, Y. Koh, T. Miyakawa, H. Ogata, and Y. Takaoka et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro J Virol 78 2004 8654 8662 (Pubitemid 39025131)
55. C. Watson, S. Jenkinson, W. Kazmierski, and T.P. Kenakin The CCR5 receptor-based mechanism of action of 873140, a potent allosteric non-competitive HIV entry-inhibitor Mol Pharmacol 67 2005 1268 1282 (Pubitemid 40410427)
56. V.M. Muniz-Medina, S. Jones, J.M. Maglich, GalardiC, R.E. Hollingsworth, and W.M. Kazmierski et al. The relative activity of 'function sparing' HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? Mol Pharmacol 75 2009 490 501
57. C. Koole, D. Wootten, J. Simms, C. Valant, R. Sridhaar, and O.L. Woodman et al. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening Mol Pharmacol 78 2010 456 465
58. R.A. Copeland, D.L. Pompliano, and T.D. Meek Drug-target residence time and its implications for lead optimization Nat Rev Drug Discov 5 2006 730 739 (Pubitemid 44323700)
59. P.J. Tummino, and R.A. Copeland Residence time of receptor-ligand complexes and its effect on biological function Biochemistry 47 2008 5481 5492 (Pubitemid 351711169)
60. R.A. Copeland Evaluation of enzyme inhibitors in drug discovery 2nd ed. 2013 Wiley Hoboken 287 344
61. G. Vauquelin, and S.J. Charlton Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action Br J Pharmacol 161 2010 488 495
62. A. Takamo, T. Suhara, Y. Ikoma, F. Yasuno, J. Maeda, and T. Ichimiya et al. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics Int J Neuropsychopharmacol 7 2004 19 26 (Pubitemid 38523803)
63. H. Shankaran, H. Resat, and H.S. Wiley Cell surface receptors for signal transduction and ligand transport: a design principles study PLoS Comput Biol 3 2007 e101
64. I. Bethani, S.S. Skånland, I. Dikic, and A. Acker-Palmer Spatial organization of transmembrane receptor signalling EMBO J 29 2010 2677 2688
65. H. Shankaran, H.S. Wiley, and H. Resat Receptor downregulation and desensitization enhance the information processing ability of signalling receptors BMC Syst Biol 1 2007 48
66. G. Milligan The prevalence maintenance, and relevance of G protein-coupled receptor oligomerization Mol Pharmacol 84 2013 158 169
67. T. Kenakin Oligomerization and allosteric modulation in G protein-coupled receptors. Prog Mol Biol Transl Sci vol. 115 2013
68. T.P. Kenakin Drug and organ selectivity: similarities and differences Adv Drug Res 15 1985 71 109
69. T.P. Kenakin New concepts in drug discovery: collateral efficacy and permissive antagonism Nat Rev Drug Discov 4 2005 919 927
70. F.J. Ehlert Analysis of allosterism in functional assays J Pharmacol Exp Ther 315 2005 740 754 (Pubitemid 41500740)
71. M.R. Price, G.L. Baillie, A. Thomas, L.A. Stevenson, M. Easson, and R. Goodwin et al. Allosteric modulation of the cannabinoid CB1 receptor Mol Pharmacol 68 2005 1484 1495 (Pubitemid 41540004)
72. E.L. Maillet, N. Pellegrini, C. Valant, B. Bucher, M. Hibert, and J.-J. Bourguignon et al. novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties FASEB J 21 2007 2124 2134 (Pubitemid 47026448)
73. O. Arunlakshana, and H.O. Schild Some quantitative uses of drug antagonists Br J Pharmacol 14 1959 48 58
74. M. Lutz, and T.P. Kenakin Quantitative molecular pharmacology and informatics in drug discovery 1999 Wiley New York
75. A. DeLean, J.M. Stadel, and R.J. Lefkowitz A ternary complex model explains the agonist-specific binding properties of adenylate cyclase coupled β-adrenergic receptor J Biol Chem 255 1980 7108 7117 (Pubitemid 11232874)
76. P. Samama, S. Cotecchia, T. Costa, and R.J. Lefkowitz A mutation-induced activated state of the β2-adrenergic receptor: extending the ternary complex model J Biol Chem 268 1993 4625 4636 (Pubitemid 23081571)
77. J.M. Weiss, P.H. Morgan, M.W. Lutz, and T.P. Kenakin The cubic ternary complex receptor-occupancy model III. Resurrecting efficacy J Theor Biol 181 1996 381 397 (Pubitemid 26333834)
78. T.P. Kenakin The Schild regression in the process of receptor classification Can J Physiol Pharmacol 60 1982 249 265 (Pubitemid 12144825)
79. T.P. Kenakin, C. Watson, V. Muniz-Medina, A. Christopoulos, and S. Novick A simple method for quantifying functional selectivity and agonist bias ACS Chem Neurosci 3 2012 193 203
80. T.P. Kenakin Perspectives in pharmacology: functional selectivity and biased receptor signaling J Pharmacol Exp Ther 336 2010 296 302
81. W.D.M. Paton, and H.P. Rang The uptake of atropine and related drugs by intestinal smooth muscle of the guinea pig in relation to acetylcholine receptors Proc R Soc Lond [Biol] 163 1965 1 44
82. T.P. Kenakin, S. Jenkinson, and C. Watson Determining the potency and molecular mechanism of action of insurmountable antagonists J Pharmacol Exp Ther 319 2006 710 723
83. L. Christmanson, P. Westermark, and C. Betsholtz Islet amyloid polypeptide stimulates cyclic AMP accumulation via the porcine calcitonin receptor Biochem Biophys Res Commun 205 1994 1226 1235
84. J. Fang, and I.A.M. de Lannoy Pharmacokinetics Biochem Pharmacol 87 2014 93 120
85. A.S.A. Roy Stifling New Cures: The True Cost of Lengthy Clinical Drug Trial. Project FDA Report March 2013 Manhattan Institute http://www.manhattan- institute.org/pdf/fda-05.pdf
86. J. Kazius, R. McGuire, and R. Bursi Derivation and validation of toxicophores for mutagenicity prediction J Med Chem 48 2005 312 320 (Pubitemid 40105270)
87. C. Merlot Computational toxicology: a tool for early safety evaluation Drug Disc Today 15 2010 16 22
88. C. Merlot In silico methods for early toxicity assessment Curr Opin Drug Disc Dev 11 2008 80 85
89. L.G. Valerio, C. Yang, K.B. Arvidson, and N.L. Kruhlak A structural feature-based computational approach for toxicological predictions Exp Opin Drug Metab Toxicol 6 2010 505 518
90. J.T. MacGregor, J.M. Collins, Y. Sugiyama, C.A. Tyson, J. Dean, and L. Smith et al. In vitro human tissue models in risk assessment: report of a concensus building workshop Toxicol Sci 59 2000 17
91. A.P. Li Screening for human ADME/Tox properties in drug discovery Drug Disc Today 6 2002 357 366
92. A.P. Li, C. Lu, J.A. Brent, C. Pham, A. Fackett, and C.E. Ruegg Cryopreserved human hepatocytes: characterization of drug-metabolizing activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential Chem Biol Interact 121 1999 17 35 (Pubitemid 29240667)
93. W. Li, D.F. Choy, M.S. Lam, T. Morgan, M.E. Sullivan, and J.M. Post Use of cultured cells of kidney origin to assess specific cytotoxic effects of nephrotoxins Toxicol In vitro 17 2003 107 113 (Pubitemid 36106497)
94. J. Hodgson ADMET - turning chemicals into drugs Nat Biotechnol 19 2001 722 726
95. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 2004 711
96. J. Arrowsmith Trial watch: phase II failures: 2008-2010 Bio Business Briefs (2011) Nat Rev Drug Discov 10 2011 328 329
97. C.T. Keith, A.A. Borisy, and Stockwell BR Multicomponent therapeutics for networked systems Nat Drug Discov 4 2005 71 85
98. S. Loew, and H. Muischnek Uber Kombinationswirkungen Naunyn Schmiedebergs Arch Exp Pathol Pharmacol 114 1926 313 326
99. S. Loewe The problem of synergism and antagonism of combined drugs Arzneimittelforschung 3 1953 285 290
100. R.J. Tallarida Revisiting the isobole and related quantitative methods for assessing drug synergism J Pharmacol Exp Ther 342 2012 2 8
101. C.I. Bliss The toxicity of poisons combined jointly Ann Appl Biol 26 1939 585 615
102. J.J. Peterson, and S.J. Novick Nonlinear blending: a useful general concept for the assessment of combination drug synergy J Recept Signal Transduct Res 27 2007 125 146 (Pubitemid 47024328)
103. R.J. Tallarida, and R.B. Raffa Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram Life Sci 58 1995 23 28
104. J.L. Benovic G-protein-coupled receptors signal victory Cell 141 2012 1148 1150
105. T.P. Kenakin Making receptors a reality: the 2012 Nobel Prize in chemistry Trends Pharmacol Sci 34 2013 2 5
106. R.S. Goody, and K.A. Johnson The original Michaelis constant: translation of the 1913 Michaelis-Menten paper. Michaelis L, Menten ML. The kinetics of invertase action Biochemistry 50 2011 8264 8269
107. J.-P. Changeux Allostery and the Monod-Wyman-Changeux model after 50 years Ann Rev Biophys 41 2012 103 133
108. D. Zolkowska, R. Jain, R.B. Rothman, J.S. Partilla, B.L. Roth, and V. Setola et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil J Pharmacol Exp Ther 329 2009 738 746
109. P.C. Jobe, L.E. Adams-Curtis, T.F. Burks, R.W. Fuller, C.C. Peck, and R.R. Ruffolo et al. The essential role of integrative biomedical sciences in protecting and contributing to the health and well being of our nation Physiologist 37 1994 79 84
110. M.J. Joyner Giant sucking sound: can physiology fill the intellectual void left by the reductionists J App Physiol 111 2011 335 342
111. O. Wolkenhauer, and S. Green The search for organizing principles as a cure against reductionism in systems medicine FEBS J 2013 10.1111/febs.12311
112. American Type Culture Collection Standards Development Organization Workgroup ASN-0002. Cell line misidentification: the beginning of the end Nat Rev Cancer 10 2010 441 448
113. S. Domcke, R. Sinha, D.A. Levine, C. Sander, and N. Schultz Evaluating cell lines as tumour models by comparison of genomic profiles Nat Commun 4 2013 2126
114. L.J. Bristow, M.S. Kramer, J. Kulagowski, S. Patel, C.I. Ragan, and G.R. Seabrook Schizophrenia and L-745, 870, a novel dopamineD4 receptor antagonist Trends Pharmacol Sci 18 1997 186 188 (Pubitemid 27283645)